Affordable Access

deepdyve-link
Publisher Website

Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study.

Authors
  • Hsu, Chung-Yuan1
  • Lin, Ming-Shyan2
  • Su, Yu-Jih1
  • Cheng, Tien-Tsai1
  • Lin, Yu-Sheng3, 4
  • Chen, Ying-Chou1
  • Chiu, Wen-Chan1
  • Chen, Tien-Hsing5
  • 1 Division of Rheumatology, Allergy, and Immunology, Department of Internal Medicine Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung.
  • 2 Division of Cardiology, Chang-Gung Memorial Hospital, Yunlin.
  • 3 Division of Cardiology, Chang Gung Memorial Hospital, Chiayi.
  • 4 School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan County.
  • 5 Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Keelung, Taiwan. , (Taiwan)
Type
Published Article
Journal
Rheumatology (Oxford, England)
Publication Date
Apr 01, 2017
Volume
56
Issue
4
Pages
620–628
Identifiers
DOI: 10.1093/rheumatology/kew457
PMID: 28039419
Source
Medline
Keywords
License
Unknown

Abstract

Diverse cancer risks are associated with different immunosuppressants in patients with SLE. CYC increases the risk of cancer, and HCQ decreases this risk in SLE patients, both in a dose-dependent manner.

Report this publication

Statistics

Seen <100 times